Capstone Energy+, Inc. (CGEH) Wins 2.6 MW Order for Argentina LNG Infrastructure

Capstone Energy Plus, Inc. (CEPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Capstone Energy+ Reports Results for First Quarter of Fiscal 2027 Gross Profit Increased 16% to $8.8 Million ​ Company Generated $5.4 Million in Operating Cash Flow ​ LOS ANGELES, CA / BUSINESS WIRE / August 12, 2026 — Capstone Energy+, Inc. (NASDAQ: CEPL) (“Capstone

Johnson & Johnson (JNJ) reported Phase 1 trial results for JNJ-6143, showing 75% of advanced prostate cancer patients had tumor shrinkage. 77% saw a 50% PSA reduction at 50 mg dose. The drug had mild to moderate side effects. JNJ acquired the therapy via Halda Therapeutics in 2025. JNJ shares closed at $263.81 on Friday.

Regeneron Pharmaceuticals (REGN) presented longer-term data from the Phase 3 C-POST trial, showing Libtayo reduced death risk by 37% in high-risk CSCC patients. The 4-year follow-up confirmed sustained disease-free survival benefits, regardless of minimal residual disease status. Libtayo has been approved in the U.S. and Europe for this indication.

Pfizer's experimental drug atirmociclib, combined with fulvestrant, showed a median progression-free survival of 9.4 months in advanced breast cancer patients, compared to 6.6 months with standard treatment. The Phase 2 trial involved 264 patients across 14 countries, with results to be presented at the ESMO Congress. The drug is not yet approved, and overall survival data is immature.

Xencor Inc. (XNCR) reported Phase 1 trial results for XmAb819, a cancer drug, showing a 45.5% response rate at the 400 mcg/kg dose. The company plans to discuss accelerated approval with the FDA and initiate a global trial comparing XmAb819 with tivozanib. Adverse events were reported in 72.1% of patients, with liver enzyme elevations being the most common.

Xencor presented Phase 1 data for XmAb819, showing tumor shrinkage in 5 of 11 advanced ccRCC patients. The company plans FDA discussions for accelerated approval in 2027. XmAb819 demonstrated a 45% confirmed objective response rate in heavily pre-treated patients. Xencor will host a webcast to discuss the results and development plans.